BCTXW

BCTXW

USD

BriaCell Therapeutics Corp. Warrant

$0.049-0.015 (-23.721%)

リアルタイム価格

Healthcare
バイオテクノロジー
カナダ

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$0.065

高値

$0.054

安値

$0.033

出来高

0.00M

企業ファンダメンタルズ

業種

バイオテクノロジー

Canada

取引統計

取引所

NCM

通貨

USD

52週レンジ

安値 $0.0332現在値 $0.049高値 $0.054

関連ニュース

GlobeNewswire

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate

もっと見る
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
GlobeNewswire

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation

もっと見る
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer

もっと見る
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
GlobeNewswire

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA

もっと見る
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer